Friday, February 10, 2012
SALT LAKE CITY, Feb. 9, 2012 (GLOBE NEWSWIRE) -- LifeVantage
Corporation (OTCBB:LFVN), maker of Protandim®, the Nrf2 Synergizer™
patented Dietary Supplement, announced today that its spokesperson,
Donny Osmond, appeared on the Dr. Phil show February 8 and shared
one of his "secrets" to his youthful appearance and
vitality-Protandim. On the heels of Donny's appearance, Protandim
ranked first among Google searches in the United States February 8,
and remains in the top among Google searches in the United States
February 9. In addition to its Google trend ranking,
LifeVantage.com visits were up nearly 300% and Protandim.com visits
were up over 800% during the same time period.
Donny Osmond, the 2009 "Dancing with the Stars" champion, said he
had discovered what he called his own "fountain of
youth"-Protandim-during his appearance on the Dr. Phil show. Donny
added that he has taken Protandim for two years at his doctor's
recommendation and has experienced many health benefits and
anti-aging results.
"This continues to be an exciting time for Protandim and
LifeVantage," said LifeVantage President and CEO, Douglas C.
Robinson. "There is an ever increasing number of Nrf2 studies in
many of the most respected universities and institutions around the
world. It is also gratifying to know that Protandim is of such
interest that people have been typing 'Protandim' in Google
searches more than any other word recently."
About Protandim, the Nrf2 Synergizer
Protandim® is a clinically demonstrated supplement that provides
substantial benefits for healthy aging. Nrf2 is a protein messenger
contained in every cell of the body. When activated, Nrf2 enters
the cell nucleus and turns on hundreds of survival genes,
defensive, stress responsive, cytoprotective genes that enable
cells to survive in the face of several different kinds of stress,
particularly oxidative stress. This patented Nrf2-activating
therapy works in a very different way than conventional antioxidant
supplements. Unlike vitamin or carotenoid-containing products that
have proven to be largely ineffective in reducing oxidative stress
caused by free radicals, Protandim is an indirect antioxidant
therapy, which stimulates the body's production of its own powerful
antioxidant enzymes and other stress-related gene products.
Protandim works at the cellular level, triggering cells to
naturally increase production of protective antioxidant enzymes
such as superoxide dismutase (SOD), catalase, and glutathione
synthase, while decreasing production of pro-inflammatory signals.
A peer-reviewed human clinical study showed that after Protandim
was taken for 30 consecutive days, important biochemical markers of
aging were decreased by an average of 40%. The study also reported
that these markers of aging were reduced in the subjects taking
Protandim to the level of a typical 20 year old. Protandim is
currently the subject of several scientific studies at universities
and research facilities. The nature and stages of the studies vary.
Under the Dietary Supplement Health and Education Act, Protandim is
considered a "dietary supplement". Protandim is not intended for
the prevention, diagnosis, treatment, mitigation or cure of any
disease. For more information about Protandim, visit
www.LifeVantage.com.
About LifeVantage Corporation
LifeVantage (OTCBB:LFVN), maker of Protandim®, the Nrf2 Synergizer™
patented dietary supplement, is a science based nutraceutical
company. LifeVantage is dedicated to visionary science that looks
to transform wellness and anti-aging internally and externally with
supplements that dramatically reduce oxidative stress at the
cellular level. The Company was founded in 2003 with corporate
headquarters in Salt Lake City, UT and operations in San Diego, CA.
For more information, visit www.LifeVantage.com.
The LifeVantage Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11617
Forward Looking Statements
This document contains forward-looking statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words and expressions reflecting optimism and
satisfaction with current prospects, as well as words such as
"believe," "hopes," "intends," "estimates," "expects," "projects,"
"plans," "anticipates" and variations thereof, identify
forward-looking statements, but their absence does not mean that a
statement is not forward-looking. Such forward-looking statements
are not guarantees of performance and the Company's actual results
could differ materially from those contained in such statements.
These forward-looking statements are based on the Company's current
expectations and beliefs concerning future events affecting the
Company and involve known and unknown risks and uncertainties that
may cause the Company's actual results or outcomes to be materially
different from those anticipated and discussed herein. These risks
and uncertainties include, among others, the potential failure or
unintended negative consequences of the implementation of the
Company's network marketing sales channel; the Company's ability to
retain independent distributors or to attract new independent
distributors on an ongoing basis; the potential for third party and
governmental actions involving the Company's network marketing
sales channel; the potential for product liability claims against
the Company; the risk that government regulators and regulations
could adversely affect the Company's business; future laws or
regulations may hinder or prohibit the production or sale of the
Company's existing product and any future products; unfavorable
publicity could materially hurt the Company's business; and the
Company's ability to protect its intellectual property rights and
the value of its product. These and other risk factors are
discussed in greater detail in the Company's Annual Report on Form
10-K and its Quarterly Report on Form 10-Q under the caption "Risk
Factors", and in other documents filed by the Company from time to
time with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the
forward-looking statements contained in this document. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this document, except as required by law.
CONTACT: Media Relations Contact:
Andrea Ramsey
(801) 432-9019
Investor Relations
Contact:
Cindy England
(801) 432-9036 -or-
John Mills (310)
954-1105 Senior Managing Director, ICR, LLC